{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T11:13:15Z","timestamp":1792321995633,"version":"4.4.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NS076386"],"award-info":[{"award-number":["NS076386"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1016\/j.nano.2013.06.012","type":"journal-article","created":{"date-parts":[[2013,7,9]],"date-time":"2013-07-09T03:16:42Z","timestamp":1373339802000},"page":"177-185","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":55,"title":["Nano-NRTIs demonstrate low neurotoxicity and high antiviral activity against HIV infection in the brain"],"prefix":"10.1016","volume":"10","author":[{"given":"Trevor","family":"Gerson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward","family":"Makarov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thulani H.","family":"Senanayake","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santhi","family":"Gorantla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larisa Y.","family":"Poluektova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serguei V.","family":"Vinogradov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nano.2013.06.012_bb0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3851\/IMP1680","article-title":"Nano-NRTIs: efficient inhibitors of HIV type-1 in macrophages with a reduced mitochondrial toxicity","volume":"21","author":"Vinogradov","year":"2010","journal-title":"Antivir Chem Chemother"},{"issue":"1","key":"10.1016\/j.nano.2013.06.012_bb0010","doi-asserted-by":"crossref","first-page":"A38","DOI":"10.1016\/j.antiviral.2010.02.388","article-title":"Efficient suppression of human immunodeficiency virus in macrophages by nano-NRTIs","volume":"86","author":"Makarov","year":"2010","journal-title":"Antiviral Res"},{"issue":"2","key":"10.1016\/j.nano.2013.06.012_bb0015","doi-asserted-by":"crossref","first-page":"A99","DOI":"10.1016\/j.antiviral.2008.12.013","article-title":"The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research","volume":"82","author":"Varatharajan","year":"2009","journal-title":"Antiviral Res"},{"issue":"6","key":"10.1016\/j.nano.2013.06.012_bb0020","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/jac\/dkq096","article-title":"Unmet therapeutic needs in the new era of combination antiretroviral therapy for HIV-1","volume":"65","author":"Taiwo","year":"2010","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.nano.2013.06.012_bb0025","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1517\/17425240903081705","article-title":"Targeting anti-HIV drugs to the CNS","volume":"6","author":"Rao","year":"2009","journal-title":"Expert Opin Drug Deliv"},{"key":"10.1016\/j.nano.2013.06.012_bb0030","first-page":"533","article-title":"Progress in antiretroviral drug delivery using nanotechnology","volume":"5","author":"Mallipeddi","year":"2010","journal-title":"Int J Nanomedicine"},{"issue":"35","key":"10.1016\/j.nano.2013.06.012_bb0035","doi-asserted-by":"crossref","first-page":"7998","DOI":"10.1002\/anie.201006565","article-title":"Shuttle-mediated drug delivery to the brain","volume":"50","author":"Malakoutikhah","year":"2011","journal-title":"Angew Chem Int Ed Engl"},{"issue":"1\u20132","key":"10.1016\/j.nano.2013.06.012_bb0040","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ijpharm.2005.01.043","article-title":"Cationic albumin conjugated pegylated nanoparticle with its transcytosis ability and little toxicity against blood-brain barrier","volume":"295","author":"Lu","year":"2005","journal-title":"Int J Pharm"},{"issue":"4","key":"10.1016\/j.nano.2013.06.012_bb0045","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1080\/10611860290031877","article-title":"Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier","volume":"10","author":"Kreuter","year":"2002","journal-title":"J Drug Target"},{"issue":"8","key":"10.1016\/j.nano.2013.06.012_bb0050","doi-asserted-by":"crossref","first-page":"903","DOI":"10.2217\/nnm.09.71","article-title":"NanoART synthesis, characterization, uptake, release and toxicology for human monocyte-macrophage drug delivery","volume":"4","author":"Nowacek","year":"2009","journal-title":"Nanomedicine (Lond)"},{"issue":"17","key":"10.1016\/j.nano.2013.06.012_bb0055","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1097\/QAD.0b013e328357f5ad","article-title":"Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice","volume":"26","author":"Dash","year":"2012","journal-title":"AIDS"},{"issue":"2","key":"10.1016\/j.nano.2013.06.012_bb0060","doi-asserted-by":"crossref","first-page":"219","DOI":"10.2174\/156720106776359230","article-title":"A review of nanocarrier-based CNS delivery systems","volume":"3","author":"Tiwari","year":"2006","journal-title":"Curr Drug Deliv"},{"issue":"2","key":"10.1016\/j.nano.2013.06.012_bb0065","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1124\/pr.58.2.3","article-title":"Multidrug resistance-associated proteins: expression and function in the central nervous system","volume":"58","author":"Dallas","year":"2006","journal-title":"Pharmacol Rev"},{"issue":"3","key":"10.1016\/j.nano.2013.06.012_bb0070","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2174\/157016206777709447","article-title":"The blood-brain barrier in neuroAIDS","volume":"4","author":"Banks","year":"2006","journal-title":"Curr HIV Res"},{"issue":"8","key":"10.1016\/j.nano.2013.06.012_bb0075","first-page":"884","article-title":"Brain dysfunction in the era of combination antiretroviral therapy: implications for the treatment of the aging population of HIV-infected individuals","volume":"11","author":"Clark","year":"2010","journal-title":"Curr Opin Investig Drugs"},{"issue":"2","key":"10.1016\/j.nano.2013.06.012_bb0080","first-page":"167","article-title":"Liver toxicity of antiretroviral drugs","volume":"2","author":"Jones","year":"2012","journal-title":"Semin Liver Dis"},{"issue":"4","key":"10.1016\/j.nano.2013.06.012_bb0085","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1310\/hct1304-189","article-title":"Renal toxicity associated with antiretroviral therapy","volume":"13","author":"Calza","year":"2012","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.nano.2013.06.012_bb0090","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.jconrel.2005.06.002","article-title":"Polyplex nanogel formulations for drug delivery of cytotoxic nucleoside analogs","volume":"107","author":"Vinogradov","year":"2005","journal-title":"J Contr Release"},{"key":"10.1016\/j.nano.2013.06.012_bb0095","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jconrel.2007.04.007","article-title":"Formulations of biodegradable Nanogel carriers with 5\u2032-triphosphates of nucleoside analogs that display a reduced cytotoxicity and enhanced drug activity","volume":"121","author":"Kohli","year":"2007","journal-title":"J Contr Release"},{"issue":"6","key":"10.1016\/j.nano.2013.06.012_bb0100","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1021\/bi048080x","article-title":"An apolipoprotein E-derived peptide mediates uptake of sterically stabilized liposomes into brain capillary endothelial cells","volume":"44","author":"Sauer","year":"2005","journal-title":"Biochemistry"},{"key":"10.1016\/j.nano.2013.06.012_bb0105","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1021\/mp0500364","article-title":"Cross-linked polymeric nanogel formulations of 5\u2032-triphosphates of nucleoside analogs: role of the cellular membrane in drug release","volume":"2","author":"Vinogradov","year":"2005","journal-title":"Mol Pharm"},{"issue":"2\u20133","key":"10.1016\/j.nano.2013.06.012_bb0110","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0166-0934(94)90124-4","article-title":"MTT colorimetric assay system for the screening of anti-orthomyxo- and anti-paramyxoviral agents","volume":"48","author":"Watanabe","year":"1994","journal-title":"J Virol Methods"},{"issue":"4","key":"10.1016\/j.nano.2013.06.012_bb0115","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1080\/13550280500187005","article-title":"Exogenous IL-7 induces Fas-mediated human neuronal apoptosis: potential effects during human immunodeficiency virus type 1 infection","volume":"11","author":"Nunnari","year":"2005","journal-title":"J Neurovirol"},{"issue":"2","key":"10.1016\/j.nano.2013.06.012_bb0120","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1212\/WNL.54.2.379","article-title":"Evaluation of antiretroviral drug efficacy for HIV-1 encephalitis in SCID mice","volume":"54","author":"Limoges","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.nano.2013.06.012_bb0125","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1021\/bc034164r","article-title":"Nanogels for oligonucleotide delivery to the brain","volume":"15","author":"Vinogradov","year":"2004","journal-title":"Bioconjug Chem"},{"issue":"6","key":"10.1016\/j.nano.2013.06.012_bb0130","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0149-2918(00)90004-3","article-title":"Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity","volume":"22","author":"Kakuda","year":"2000","journal-title":"Clin Ther"},{"issue":"5","key":"10.1016\/j.nano.2013.06.012_bb0135","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1002\/jcb.22196","article-title":"Reactive oxygen species-induced cell death of rat primary astrocytes through mitochondria-mediated mechanism","volume":"107","author":"Wang","year":"2009","journal-title":"J Cell Biochem"},{"issue":"Suppl. 2","key":"10.1016\/j.nano.2013.06.012_bb0140","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/13550280290167993","article-title":"Murine models for human immunodeficiency virus type 1-associated dementia: the development of new treatment testing paradigms","volume":"8","author":"Persidsky","year":"2002","journal-title":"J Neurovirol"},{"issue":"1\u20132","key":"10.1016\/j.nano.2013.06.012_bb0145","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/S0006-8993(98)00139-5","article-title":"Low blood-brain barrier permeability to azidothymidine (AZT), 3TC, and thymidine in the rat","volume":"791","author":"Wu","year":"1998","journal-title":"Brain Res"},{"issue":"3","key":"10.1016\/j.nano.2013.06.012_bb0150","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1189\/jlb.68.3.413","article-title":"Mononuclear phagocytes mediate blood-brain barrier compromise and neuronal injury during HIV-1-associated dementia","volume":"68","author":"Persidsky","year":"2000","journal-title":"J Leukoc Biol"},{"issue":"7","key":"10.1016\/j.nano.2013.06.012_bb0155","doi-asserted-by":"crossref","first-page":"4345","DOI":"10.4049\/jimmunol.179.7.4345","article-title":"Copolymer-1 induces adaptive immune anti-inflammatory glial and neuroprotective responses in a murine model of HIV-1 encephalitis","volume":"179","author":"Gorantla","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.nano.2013.06.012_bb0160","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/978-94-007-2869-1_16","article-title":"Iatrogenic mitochondriopathies: a recent lesson from nucleoside\/nucleotide reverse transcriptase inhibitors","volume":"942","author":"Leung","year":"2012","journal-title":"Adv Exp Med Biol"},{"issue":"5","key":"10.1016\/j.nano.2013.06.012_bb0165","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/mus.23414","article-title":"Ocular neuropathy in peripheral neuropathies","volume":"46","author":"Evliyaoglu","year":"2012","journal-title":"Muscle Nerve"},{"issue":"2","key":"10.1016\/j.nano.2013.06.012_bb0170","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1097\/CND.0b013e318221256f","article-title":"Neuromuscular manifestations of HIV\/AIDS","volume":"13","author":"Harrison","year":"2011","journal-title":"J Clin Neuromuscul Dis"},{"issue":"6","key":"10.1016\/j.nano.2013.06.012_bb0175","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/j.jpain.2011.03.006","article-title":"Pain in HIV: an evolving epidemic","volume":"12","author":"Wiebe","year":"2011","journal-title":"J Pain"},{"issue":"3","key":"10.1016\/j.nano.2013.06.012_bb0180","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2174\/157016206777709384","article-title":"Mechanisms of neuronal injury and death in HIV-1 associated dementia","volume":"4","author":"Kaul","year":"2006","journal-title":"Curr HIV Res"},{"issue":"1\u20132","key":"10.1016\/j.nano.2013.06.012_bb0185","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jns.2012.05.030","article-title":"Mitochondria, oxidative stress and neurodegeneration","volume":"322","author":"Federico","year":"2012","journal-title":"J Neurol Sci"},{"issue":"8\u20139","key":"10.1016\/j.nano.2013.06.012_bb0190","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.progpolymsci.2007.05.014","article-title":"Nanomedicine in the diagnosis and therapy of neurodegenerative disorders","volume":"32","author":"Kabanov","year":"2007","journal-title":"Prog Polym Sci"},{"issue":"2","key":"10.1016\/j.nano.2013.06.012_bb0195","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.colsurfb.2008.07.004","article-title":"Biodistribution of colloidal gold nanoparticles after intravenous administration: effect of particle size","volume":"66","author":"Sonavane","year":"2008","journal-title":"Colloids Surf B Biointerfaces"},{"issue":"12","key":"10.1016\/j.nano.2013.06.012_bb0200","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1016\/j.biomaterials.2007.12.037","article-title":"Particle size-dependent organ distribution of gold nanoparticles after intravenous administration","volume":"29","author":"De Jong","year":"2008","journal-title":"Biomaterials"},{"issue":"6","key":"10.1016\/j.nano.2013.06.012_bb0205","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1016\/j.biomaterials.2009.11.007","article-title":"Potential role of size and hemodynamics in the efficacy of vascular-targeted spherical drug carriers","volume":"31","author":"Charoenphol","year":"2010","journal-title":"Biomaterials"},{"issue":"2","key":"10.1016\/j.nano.2013.06.012_bb0210","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2217\/nnm.09.103","article-title":"Nanogels in the race for drug delivery","volume":"5","author":"Vinogradov","year":"2010","journal-title":"Nanomedicine (Lond)"},{"issue":"3","key":"10.1016\/j.nano.2013.06.012_bb0215","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.tins.2011.12.006","article-title":"Rodent models for HIV-associated neurocognitive disorders","volume":"35","author":"Gorantla","year":"2012","journal-title":"Trends Neurosci"}],"container-title":["Nanomedicine: Nanotechnology, Biology and Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963413003377?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1549963413003377?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T15:06:17Z","timestamp":1727795177000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1549963413003377"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,1]]}},"alternative-id":["S1549963413003377"],"URL":"https:\/\/doi.org\/10.1016\/j.nano.2013.06.012","relation":{},"ISSN":["1549-9634"],"issn-type":[{"value":"1549-9634","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nano-NRTIs demonstrate low neurotoxicity and high antiviral activity against HIV infection in the brain","name":"articletitle","label":"Article Title"},{"value":"Nanomedicine: Nanotechnology, Biology and Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nano.2013.06.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}